Our strategy
GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, immunology/respiratory, and oncology,
Our long-term priorities
We’re uniting science, technology and talent to make a difference in more people’s lives. We don’t just want to find new, better medicines and vaccines. We’re working to get better at finding them in ways that are faster, more effective, and more predictable. This is reflected in the continued success of our R&D pipeline, which saw significant progress in 2022. Strategic partnerships are critical to opening up new avenues of discovery. We have important collaborations, including with the University of Oxford on neurodegenerative diseases, Kings College London on cancer treatment and 23andMe on genetics and genomics.
-
New approvals since 2017
20+ -
Potential new vaccines and medicines in phase III and registration since 2017
23 -
Vaccines and medicines in our pipeline
69
We’re confident in our future. Our bold ambitions for patients are reflected in new commitments to growth and a significant step-change in delivery by 2026. This means more GSK vaccines and medicines, including innovative new products, will reach more people who need them than ever before.
-
Patients: packs of medicines and doses of vaccines delivered in 2022
2.3bn -
Shareholders: per share dividend in 2022
61.25p -
Society: corporate income tax paid; in addition we pay duties, levies, transactional and employment taxes
£1.3bn
Being a responsible business means getting ahead of disease together in the right way. We therefore need to consider ESG impacts across everything we do, from the lab to the patient. We have identified six ESG focus areas that address what is most material to our business and the issues that matter to our stakeholders. These focus areas are access to healthcare, global health and health security, environment, diversity, equity and inclusion, ethical standards, product governance.
Our culture
Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing are the foundations for how, together, we’ll deliver for our patients, shareholders and GSK people.
Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.
The Code
Meet our Outstanding people
WHAT’S YOUR ANGLE?
Our film series brings together our people from teams across the world to discuss the issues that matter across the themes of diversity, equity and inclusion, and explore their different perspectives.
